Samuel M. Brown
A5073422869- Sepsis Diagnosis and Treatment
- Intensive Care Unit Cognitive Disorders
- COVID-19 Clinical Research Studies
- Respiratory Support and Mechanisms
- Family and Patient Care in Intensive Care Units
- SARS-CoV-2 and COVID-19 Research
- Hemodynamic Monitoring and Therapy
- Cardiac Arrest and Resuscitation
- Emergency and Acute Care Studies
- Mormonism, Religion, and History
- Long-Term Effects of COVID-19
- Palliative Care and End-of-Life Issues
- Vaccine Coverage and Hesitancy
- Cardiac, Anesthesia and Surgical Outcomes
- Ultrasound in Clinical Applications
- Pneumonia and Respiratory Infections
- American Constitutional Law and Politics
- Influenza Virus Research Studies
- Archaeology and Natural History
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare Decision-Making and Restraints
- Respiratory viral infections research
- Nosocomial Infections in ICU
- Religious Studies and Spiritual Practices
- Heart Rate Variability and Autonomic Control
Intermountain Medical Center
2016-2025
University of Utah
2016-2025
Intermountain Healthcare
2016-2025
Vanderbilt University Medical Center
2021-2025
Clark Atlanta University
2025
Association Clinique et Thérapeutique Infantile du Val de Marne
2024
National Heart Lung and Blood Institute
2023-2024
Hennepin County Medical Center
2021-2024
Atrium Health Wake Forest Baptist
2021-2024
American Society of Echocardiography
2024
Prolonged symptom duration and disability are common in adults hospitalized with severe coronavirus disease 2019 (COVID-19). Characterizing return to baseline health among outpatients milder COVID-19 illness is important for understanding the full spectrum of COVID-19-associated tailoring public messaging, interventions, policy. During April 15-June 25, 2020, telephone interviews were conducted a random sample aged ≥18 years who had first positive reverse transcription-polymerase chain...
Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir symptomatic, nonhospitalized Covid-19 who are at high risk for progression prevents hospitalization is uncertain.We conducted a randomized, double-blind, placebo-controlled trial involving had symptom onset within previous 7 days and least one factor (age ≥60 years, obesity, or certain coexisting medical conditions). Patients were randomly...
A comprehensive understanding of the benefits COVID-19 vaccination requires consideration disease attenuation, determined as whether people who develop despite have lower severity than unvaccinated people.
To characterize the clinical severity of covid-19 associated with alpha, delta, and omicron SARS-CoV-2 variants among adults admitted to hospital compare effectiveness mRNA vaccines prevent admissions related each variant.
BackgroundLY-CoV555, a neutralizing monoclonal antibody, has been associated with decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients coronavirus disease 2019 (Covid-19). Data are needed on effect this antibody patients who hospitalized Covid-19.MethodsIn platform trial therapeutic agents, we randomly assigned had Covid-19 without end-organ failure 1:1 ratio to receive either LY-CoV555 matching placebo. In addition, all received...
Data are not complete for all characteristics in the table; denominators
Data on the efficacy of hydroxychloroquine for treatment coronavirus disease 2019 (COVID-19) are needed.
Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first vaccines approved use under an Emergency Use Authorization (EUA) in United States (1-3). In evaluation 24 hospitals 14 states,* effectiveness of partial or full vaccination† with Pfizer-BioNTech Moderna against COVID-19-associated hospitalization was assessed among adults years. Among 417 hospitalized (including 187 case-patients 230 controls), median age...
Rationale: Severe sepsis and septic shock are leading causes of intensive care unit (ICU) admission, morbidity, mortality. The effect compliance with management guidelines on outcomes is unclear.Objectives: To assess the mortality a severe bundle.Methods: Observational study bundle as part quality improvement project in 18 ICUs 11 hospitals Utah Idaho.Measurements Main Results: Among 4,329 adult subjects or admitted to from emergency department between January 2004 December 2010, hospital...
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability protection. In an evaluation at 21 hospitals in 18 states, the duration mRNA vaccine (Pfizer-BioNTech or Moderna) (VE) was assessed among adults aged ≥18 years. Among 3,089 hospitalized (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), median age 59 years,...
Sepsis is a common syndrome with substantial morbidity and mortality. A combination of vitamin C, thiamine, corticosteroids has been proposed as potential treatment for patients sepsis.To determine whether hydrocortisone every 6 hours increases ventilator- vasopressor-free days compared placebo in sepsis.Multicenter, randomized, double-blind, adaptive-sample-size, placebo-controlled trial conducted adult sepsis-induced respiratory and/or cardiovascular dysfunction. Participants were enrolled...
Community and close contact exposures continue to drive the coronavirus disease 2019 (COVID-19) pandemic. CDC other public health authorities recommend community mitigation strategies reduce transmission of SARS-CoV-2, virus that causes COVID-19 (1,2). Characterization can be difficult assess when widespread is occurring, especially from asymptomatic persons within inherently interconnected communities. Potential exposures, such as with a person confirmed COVID-19, have primarily been...
Intravenous fluids and vasopressor agents are commonly used in early resuscitation of patients with sepsis, but comparative data for prioritizing their delivery limited.
Health care personnel (HCP) caring for patients with coronavirus disease 2019 (COVID-19) might be at high risk contracting SARS-CoV-2, the virus that causes COVID-19. Understanding prevalence of and factors associated SARS-CoV-2 infection among frontline HCP who COVID-19 are important protecting both their patients. During April 3-June 19, 2020, serum specimens were collected from a convenience sample worked 13 geographically diverse academic medical centers in United States, tested...
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) are effective at preventing COVID-19-associated hospitalization (1-3). However, how well protect against the most severe outcomes of these hospitalizations, including invasive mechanical ventilation (IMV) or death is uncertain. Using a case-control design, vaccine effectiveness (VE) IMV in-hospital was evaluated among adults aged ≥18 years hospitalized 21 U.S. medical centers during March 11, 2021-January 24, 2022....
Most persons infected with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), develop virus-specific antibodies within several weeks, but antibody titers might decline over time. Understanding timeline of is important for interpreting SARS-CoV-2 serology results. Serum specimens were collected from a convenience sample frontline health care personnel at 13 hospitals and tested to during April 3-June 19, 2020, again approximately 60 days later assess this timeline. The...
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage increases in the United States, there is a need to understand real-world effectiveness against disease 2019 (COVID-19) and among people at increased risk for poor outcomes.In multicenter case-control analysis of US adults hospitalized March 11-May 5, 2021, we evaluated vaccine prevent COVID-19 hospitalizations by comparing odds prior with messenger RNA (mRNA) (Pfizer-BioNTech or Moderna) between cases...
Monovalent COVID-19 mRNA vaccines, designed against the ancestral strain of SARS-CoV-2, successfully reduced COVID-19-related morbidity and mortality in United States globally (1,2). However, vaccine effectiveness (VE) COVID-19-associated hospitalization has declined over time, likely related to a combination factors, including waning immunity and, with emergence Omicron variant its sublineages, immune evasion (3). To address these on September 1, 2022, Advisory Committee Immunization...